Alexiev Borislav A, Darwin Peter E, Goloubeva Olga, Ioffe Olga B
Department of Pathology, University of Maryland Medical Center, 22 S. Greene Street, Baltimore, MD 21201, USA.
Cancer. 2009 Feb 25;117(1):40-5. doi: 10.1002/cncy.20014.
The objectives of this study were to evaluate the role of endoscopic ultrasonography (EUS)-guided fine-needle aspiration (FNA) in the preoperative diagnosis of pancreatic endocrine tumors (PETs) and to investigate whether the Ki-67 index determined on cytologic material could help predict their behavior.
The study included 10 men and 5 women (ratio of men to women, 2:1) with a mean age of 62.4 years (range, 40-79 years). Diff-Quik- and Papanicolaou-stained FNA samples were analyzed retrospectively, and immunocytochemical stains were performed for chromogranin A, synaptophysin, vimentin, alpha-1-antitrypsin, and Ki-67 on cell block sections. The Ki-67 index was evaluated by using digital image-analysis software and was correlated with follow-up (mean, 21.5 months; range, 2-43 months).
The overall survival was rate 86.7% (13 of 15 patients). Seven of 15 patients (46.7%) patients developed lymph node and/or hematogenous metastases. The Ki-67 index in PETs with no metastases was lower (mean, 6.3%; range, 2%-13%) than in clinically aggressive (metastatic) tumors (mean, 7.7%; range, 3%-27%; P = .03). None of the tumors that had a Ki-67 index < or =2% were metastatic. Both patients who died of disease had a Ki-67 index of 4%.
Although tumors with metastatic potential tended to exhibit a slightly higher Ki-67 index, there was a significant overlap with nonmetastatic tumors, and PETs that had a very low proliferative rate still could behave aggressively; therefore, the authors concluded that the Ki-67 index does not predict the risk of disease progression in patients with PETs.
本研究的目的是评估内镜超声引导下细针穿刺活检(EUS-FNA)在胰腺内分泌肿瘤(PETs)术前诊断中的作用,并研究通过细胞学材料确定的Ki-67指数是否有助于预测其行为。
该研究纳入了10名男性和5名女性(男女比例为2:1),平均年龄为62.4岁(范围40-79岁)。对Diff-Quik和巴氏染色的FNA样本进行回顾性分析,并在细胞块切片上对嗜铬粒蛋白A、突触素、波形蛋白、α-1抗胰蛋白酶和Ki-67进行免疫细胞化学染色。使用数字图像分析软件评估Ki-67指数,并与随访结果(平均21.5个月;范围2-43个月)相关联。
总生存率为86.7%(15例患者中的13例)。15例患者中有7例(46.7%)发生淋巴结和/或血行转移。无转移的PETs中的Ki-67指数(平均6.3%;范围2%-13%)低于临床侵袭性(转移性)肿瘤(平均7.7%;范围为3%-27%;P = 0.03)。Ki-67指数≤2%的肿瘤均无转移。两名死于疾病的患者的Ki-67指数均为4%。
尽管具有转移潜能的肿瘤往往表现出略高的Ki-67指数,但与非转移性肿瘤有显著重叠,增殖率极低的PETs仍可能具有侵袭性;因此,作者得出结论,Ki-67指数不能预测PETs患者疾病进展的风险。